Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

2.

An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.

Steers W, Corcos J, Foote J, Kralidis G.

BJU Int. 2005 Mar;95(4):580-6. Erratum in: BJU Int. 2005 Jun;95(9):1385-6.

3.

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.

Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE, Huang M, Ridder AM.

J Urol. 2004 Nov;172(5 Pt 1):1919-24.

PMID:
15540755
4.

Trospium chloride (Sanctura): another anticholinergic for overactive bladder.

[No authors listed]

Med Lett Drugs Ther. 2004 Aug 2;46(1188):63-4. No abstract available.

PMID:
15289745
5.

Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Hashim H, Abrams P.

Drugs. 2004;64(15):1643-56. Review.

PMID:
15257626
6.

Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial.

Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S; Trospium Study Group..

J Urol. 2004 Jun;171(6 Pt 1):2311-5, quiz 2435.

PMID:
15126811
7.

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.

Haab F, Stewart L, Dwyer P.

Eur Urol. 2004 Apr;45(4):420-9; discussion 429. Review.

PMID:
15041104
8.

Management of overactive bladder.

Ouslander JG.

N Engl J Med. 2004 Feb 19;350(8):786-99. Review. No abstract available.

PMID:
14973214
9.

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.

Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group..

BJU Int. 2004 Feb;93(3):303-10.

PMID:
14764127
10.

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

Chapple CR, Araño P, Bosch JL, De Ridder D, Kramer AE, Ridder AM.

BJU Int. 2004 Jan;93(1):71-7. Erratum in: BJU Int. 2004 May;93(7):1135.

PMID:
14678372
11.

Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.

Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Brühl B, Höfner K, Jonas U.

World J Urol. 2003 May;20(6):392-9. Epub 2003 Mar 28.

PMID:
12811500
12.

Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder.

Lee JG, Hong JY, Choo MS, Kwon HY, Chung DY, Lee KS, Lee JY, Lee T.

Int J Urol. 2002 May;9(5):247-52.

13.

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, Roach M, Miklos J, Saltzstein D, Boone T, Staskin DR, Albrecht D; Overactive Bladder: Judging Effective Control and Treatment Study Group..

Mayo Clin Proc. 2001 Apr;76(4):358-63.

PMID:
11322350
14.

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A; Tolterodine Study Group..

Urology. 2001 Mar;57(3):414-21.

PMID:
11248608
15.

Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.

Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS.

J Urol. 1999 Jun;161(6):1809-12.

PMID:
10332441
16.
17.

Supplemental Content

Support Center